Operating margin

FY 2025

26.5% " "

27.5% to 28% " "

raised

Healthcare Revenue

FY 2025

no prior guidance

$1,500 million to $1,530 million "

no prior guidance

Non-GAAP Operating Profit

FY 2025

no prior guidance

$413 million to $428 million "

no prior guidance

Non-GAAP EPS

FY 2025

no prior guidance

$5.10 to $5.40 "

no prior guidance

Technology Boards and Instruments Shipments

FY 2025

no prior guidance

240,000 to 260,000 "

no prior guidance

Margin Expansion & Cost Efficiency

Consistently discussed in Q1–Q3 with a focus on improving gross/operating margins through project rationalization, cost cuts, and manufacturing efficiencies. " " " " "

Q4 emphasized a raised operating margin guidance for 2025 (27.5%–28%), detailing continued benefits from portfolio rationalization and further cost structure optimization. " " "

Ongoing improvement with increased confidence and more ambitious guidance.

Robust Healthcare Revenue & Contracting Growth

Q1–Q3 highlighted strong hospital conversions, robust contracting activity (including over $100M in incremental contract value in Q1), and healthy revenue growth trends in healthcare, albeit with some consumer headwinds. " " " "

In Q4, healthcare revenues grew 10% with record new contracts valued at $432M, driven by strong consumables and service performance, reinforcing a healthy pipeline for future growth. " " "

Sustained robust growth with continued consolidation of hospital contracting and revenue expansion.

Manufacturing Transition to Malaysia

Q1 through Q3 detailed a significant shift of high‐volume sensor production to Malaysia with noted margin improvements and cost efficiencies; progress included over two‐thirds of production moved in Q1 and ongoing benefits in Q2 and Q3. " " "

Q4 reiterated the expansion of the global manufacturing footprint with enhanced flexibility to shift additional production from Mexico to Malaysia, partly as a contingency against tariff uncertainties. " "

Ongoing positive process with strategic flexibility and continued operational benefits.

Legal & Litigation Risks (Apple, patents, trade secrets)

Q1 mentioned the burden of litigation expenses; Q2 and Q3 provided detailed updates on trade secret and patent cases (including bench trial commencement and patent defense), reflecting significant legal activity. " " "

Q4 focused on continuing litigation against Apple—including their recent ITC appeal and awaiting decisions on trade secret retrial—indicating that legal risks remain active. "

Persistent and ongoing litigation with neutral sentiment; legal risks continue to be a long‐term factor.

Consumer Business Separation & Volatility

Q1 initiated discussion on evaluating consumer separation options; Q2 presented multiple pathways (JV, spin-off, sale) with potential margin impact; Q3 offered detailed analysis of consumer revenue volatility amid market challenges. " " "

Q4 reported that the consumer business (Sound United) is in later stages of being classified as held-for-sale and being removed from non-GAAP financials, while also noting volatility driven by seasonal respiratory trends and tariff concerns. " " "

Continued pursuit of separation with volatility management; strategic benefits are anticipated despite short-term market fluctuations.

OEM Order Dependency & Shipment Volume Fluctuations

Q1 highlighted OEM dependency causing fluctuations (a dip to 50,000 units) with expectations for recovery; Q2 and Q3 noted incrementally improved driver shipments and normalized OEM ordering patterns. " " "

Q4 discussion focused more on shipment volumes (65,000 technology boards and monitors and nearly 235,000 full year shipments) with less emphasis on OEM dependency issues, indicating a normalization of ordering patterns. " "

Reduced emphasis on volatility as OEM order patterns appear to be stabilizing and returning to normal levels.

Innovation in Healthcare Monitoring & New Product Development

Q2 and Q3 placed strong emphasis on innovation—highlighting new product platforms (ORi, Radius VSM), advanced analytics, and the integration of hemodynamic monitoring—while Q1 mentioned product growth in capnography and brain monitoring indirectly supporting the core healthcare business. " " "

Q4 shifted focus toward refocusing on core healthcare monitoring, with leadership emphasizing expanded continuous and hemodynamic monitoring opportunities, underlining an invigorated product pipeline and strategic innovation. " " " "

Increased strategic prioritization of innovation with a sharper focus on expanding healthcare monitoring capabilities.

Revenue Sustainability & Seasonality Concerns

Q1 detailed solid healthcare revenues despite a 2% decline (normalized by strong contracting) and discussed seasonal patterns; Q2 and Q3 emphasized robust hospital conversion, steady backlog, and seasonality factors in guidance. " " "

Q4 acknowledged an extra week in the fiscal year and normalized seasonal revenue distribution for 2025, while citing strong Q4 revenue performance and robust contracting as signs of sustained growth. " " "

Improved clarity with well-managed seasonality and a more sustainable revenue outlook moving forward.

Supply Chain Disruptions & Tariff Uncertainties

Not mentioned in Q1–Q3.

Q4 raised tariff uncertainties—particularly regarding 25% of healthcare COGS from Mexico—and outlined contingency plans leveraging the Malaysia facility, though no broader supply chain issues were noted. " "

An emerging topic in Q4 driven by potential tariff impacts; proactive measures are in place despite minimal supply chain disruptions.

Strategic Portfolio Optimization

In Q1, the company explored options for consumer separation as part of portfolio optimization; Q2 expanded on the separation strategies and cost optimization measures; Q3 focused on de-emphasizing underperforming products and realigning R&D spend. " " "

Q4 highlighted a comprehensive review of the R&D and product portfolio, with deliberate actions to rightsize costs, rationalize projects, and focus on core healthcare, directly contributing to margin improvements. " " "

Ongoing and sharpening focus with clear positive impact on profitability and operational efficiency.